Cover Image
市場調查報告書

霍亂 : 開發平台分析

Cholera - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246032
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
霍亂 : 開發平台分析 Cholera - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 45 Pages
簡介

所謂霍亂,是以霍亂菌為病原體的急性感染疾病,人感染時不會疼痛,會發生水分多的腹瀉。感染後,從數小時最遲在5日內出現症狀。症狀通常為輕症,不過也有達到重症的情況。主要的前兆、症狀為心律的劇增,及皮膚的彈性低、血壓低、喉嚨的乾渴、筋痙攣等。未治療的情況也可能引起休克,數小時便死亡。

本報告提供全球各國的霍亂治療用的開發中產品的開發情形相關分析、產品開發、上市的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

霍亂概要

治療藥的開發

  • 霍亂的開發中產品:概要
  • 霍亂的開發中產品:比較分析

各企業開發中的霍亂治療藥

大學/研究機關研究中的霍亂治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

霍亂治療藥:開發中的產品一覽(各企業)

霍亂治療藥:研究中的產品一覽(各大學/研究機關)

霍亂開發治療藥的企業

  • Akthelia pharmaceuticals ehf
  • Beijing Minhai Biotechnology Co., Ltd
  • PaxVax

霍亂:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AKT-10082
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 三價值霍亂疫苗
  • crofelemer的DR(延遲放出)AKT-10082
  • IMSUTMR-1501
  • 霍亂、格巴二氏症候群用肽
  • PXVX-0200

霍亂治療藥:開發中產品的最新趨勢

霍亂治療藥:開發暫停的產品

霍亂治療藥:開發中止的產品

霍亂相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8232IDB

Summary

Global Markets Direct's, 'Cholera - Pipeline Review, H2 2016', provides an overview of the Cholera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cholera
  • The report reviews pipeline therapeutics for Cholera by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cholera therapeutics and enlists all their major and minor projects
  • The report assesses Cholera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cholera

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cholera
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cholera Overview
  • Therapeutics Development
    • Pipeline Products for Cholera - Overview
    • Pipeline Products for Cholera - Comparative Analysis
  • Cholera - Therapeutics under Development by Companies
  • Cholera - Therapeutics under Investigation by Universities/Institutes
  • Cholera - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Cholera - Products under Development by Companies
  • Cholera - Products under Investigation by Universities/Institutes
  • Cholera - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • MSD Wellcome Trust Hilleman Laboratories, Pvt. Ltd.
  • Cholera - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cholera (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cholera vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cholvax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crofelemer DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gram-negative bacterial infections vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMSUTMR-1501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cholera - Dormant Projects
  • Cholera - Discontinued Products
  • Cholera - Product Development Milestones
    • Featured News & Press Releases
      • Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine
      • Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cholera, H2 2016
  • Number of Products under Development for Cholera - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Cholera - Pipeline by MSD Wellcome Trust Hilleman Laboratories, Pvt. Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cholera - Dormant Projects, H2 2016
  • Cholera - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cholera, H2 2016
  • Number of Products under Development for Cholera - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top